Literature DB >> 6595962

Disposition of radiolabeled imipenem and cilastatin in normal human volunteers.

S R Norrby, J D Rogers, F Ferber, K H Jones, A G Zacchei, L L Weidner, J L Demetriades, D A Gravallese, J Y Hsieh.   

Abstract

In the first of two successive studies, four healthy male subjects received 500 mg of 14C-labeled imipenem alone and together with 500 mg of unlabeled cilastatin sodium. In the second study, the same subjects were given 250 mg of 14C-labeled cilastatin sodium alone and together with 250 and 1,000 mg of cold imipenem. Concentrations of imipenem and cilastatin in plasma, urine, and feces were assayed by high-pressure liquid chromatography and radiometry. Plasma concentrations of imipenem assayed radiometrically were higher than those measured by high-pressure liquid chromatography. In one subject studied at the end of drug administration, the open lactam metabolite of imipenem represented 9% of the radioactivity. Plasma levels of cilastatin determined by high-pressure liquid chromatography and radiometry were virtually identical. Urinary recovery of imipenem varied between 12 and 42% of the dose when that drug was given alone but increased to between 64 and 75% when administered with cilastatin sodium at a 1:1 ratio. Almost all radioactivity of imipenem was recovered in the urine within 96 h after drug administration. The open lactam metabolite, resulting from the metabolism of imipenem in the kidneys by a dipeptidase, dehydropeptidase-I, represented 80 to 90% of the effluent radioactivity when imipenem was given alone and about 20% when cilastatin sodium was coadministered. Renal excretion of cilastatin followed closely that of imipenem. Almost all of the administered radioactivity was recovered in 24 h, and about 75% of the dose was recovered as unchanged cilastatin within 6 h. The N-acetyl metabolite of cilastatin was found to represent about 12% of the total radioactivity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6595962      PMCID: PMC180000          DOI: 10.1128/AAC.26.5.707

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Safety and tolerance comparison of imipenem-cilastatin to cephalothin and cefazolin.

Authors:  G B Calandra; F M Ricci; C Wang; K R Brown
Journal:  J Antimicrob Chemother       Date:  1983-12       Impact factor: 5.790

2.  Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans.

Authors:  S R Norrby; K Alestig; F Ferber; J L Huber; K H Jones; F M Kahan; M A Meisinger; J D Rogers
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

3.  Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors.

Authors:  S R Norrby; K Alestig; B Björnegård; L A Burman; F Ferber; J L Huber; K H Jones; F M Kahan; J S Kahan; H Kropp; M A Meisinger; J G Sundelof
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

Review 4.  Thienamycin: development of imipenen-cilastatin.

Authors:  F M Kahan; H Kropp; J G Sundelof; J Birnbaum
Journal:  J Antimicrob Chemother       Date:  1983-12       Impact factor: 5.790

5.  MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities.

Authors:  H Kropp; J G Sundelof; J S Kahan; F M Kahan; J Birnbaum
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

6.  Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase.

Authors:  H Kropp; J G Sundelof; R Hajdu; F M Kahan
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

7.  In vitro activity of N-formimidoyl thienamycin in comparison with cefotaxime, moxalactam, and ceftazidime.

Authors:  L Verbist; J Verhaegen
Journal:  Antimicrob Agents Chemother       Date:  1981-03       Impact factor: 5.191

  7 in total
  25 in total

1.  Pharmacokinetics of meropenem in subjects with various degrees of renal impairment.

Authors:  B A Christensson; I Nilsson-Ehle; M Hutchison; S J Haworth; B Oqvist; S R Norrby
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

2.  Pharmacokinetics of the penem CP-65,207 and its separate stereoisomers in humans.

Authors:  G Foulds; A K Knirsch; J D Lazar; T G Tensfelt; N Gerber
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

3.  Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid.

Authors:  J G Coen van Hasselt; Matthew L Rizk; Mallika Lala; Cynthia Chavez-Eng; Sandra A G Visser; Thomas Kerbusch; Meindert Danhof; Gauri Rao; Piet H van der Graaf
Journal:  Br J Clin Pharmacol       Date:  2016-04-01       Impact factor: 4.335

4.  Imipenem concentrations in colorectal surgery and impact on the colonic microflora.

Authors:  L Kager; B Brismar; A S Malmborg; C E Nord
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

5.  Bile levels of imipenem in patients with T-drain following the administration of imipenem/cilastatin.

Authors:  M Mayer; C Tophof; W Opferkuch
Journal:  Infection       Date:  1988 Jul-Aug       Impact factor: 3.553

6.  Degradation kinetics of imipenem in normal saline and in human serum.

Authors:  D J Swanson; C DeAngelis; I L Smith; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

7.  Determination of imipenem and cilastatin in serum and tissue by high-pressure liquid chromatography.

Authors:  R Krausse; U Ullmann
Journal:  Infection       Date:  1986 Sep-Oct       Impact factor: 3.553

8.  Pharmacokinetics of imipenem-cilastatin in patients with renal insufficiency undergoing continuous ambulatory peritoneal dialysis.

Authors:  P Somani; E H Freimer; M L Gross; J T Higgins
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

Review 9.  Extrahepatic metabolism of drugs in humans.

Authors:  D R Krishna; U Klotz
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

Review 10.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.